ATYR aTYR PHARMA INC
Price Chart
Executive Summary
aTyr Pharma filed an 8-K with an investor presentation detailing plans for a new Phase 3 study (C-006) of efzofitimod in pulmonary sarcoidosis, following a Type C meeting with the FDA. The presentation highlights a refined study design focusing on restrictive lung disease patients with FVC as the primary endpoint, and reports ~$68.3M in cash as of March 31, 2026. The filing is a routine business update with no new financial results or material definitive agreements.
Actionable Insight
The filing is a routine investor presentation update with no new financial data. The key catalyst to watch is the IND filing for C-006 in June 2026 and subsequent Phase 3 enrollment updates. The refined trial design targeting restrictive lung disease patients may reduce regulatory risk but does not change the binary outcome risk of the Phase 3 readout.
Key Facts
- Planned Phase 3 study (C-006) of efzofitimod in pulmonary sarcoidosis with FVC as primary endpoint, targeting restrictive lung disease patients.
- FDA Type C meeting outcome: FDA supported FVC and KSQ-L as clinically meaningful endpoints; company concluded FVC is more appropriate for C-006.
- Company plans to file IND for C-006 in June 2026.
- EFZO-FIT trial (largest interventional pulmonary sarcoidosis trial) did not meet primary endpoint but showed trends in steroid reduction and QoL improvements.
- Cash, restricted cash, cash equivalents and available-for-sale investments of ~$68.3M as of March 31, 2026.
- EFZO-CONNECT Phase 2 study in SSc-ILD ongoing; enrollment completion expected in 1H 2026.
- Preclinical candidate ATYR0101 for fibrosis undergoing IND-enabling studies.
Financial Impact
No new financial results reported. Cash position of ~$68.3M as of March 31, 2026.
Risk Factors
- EFZO-FIT missed its primary endpoint; Phase 3 success is not assured.
- Cash runway of ~$68.3M may require additional financing to complete the Phase 3 program.
- Regulatory path for FVC as primary endpoint in pulmonary sarcoidosis is not fully established.
Market Snapshot
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001339970-26-000036 |
| Document: atyr-ex99_1.htm | 0001339970-26-000036 |
| Document: 0001339970-26-000036-index-headers.html | 0001339970-26-000036 |
| Document: 0001339970-26-000036-index.html | 0001339970-26-000036 |
| Document: 0001339970-26-000036.txt | 0001339970-26-000036 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 11, 2026
5d ago
|
Institutional Cluster
| $0.4754 $0.4404 | ▼ −7.36% | ▼ −7.90% | $0.4480 (−5.76%) |
|
Jun 8, 2026
8d ago
|
8-K
| $0.4556 $0.4684 | ▼ −2.81% | ▼ −4.39% | $0.4480 (+1.67%) |
|
Jun 1, 2026
15d ago
|
8-K
| $0.5200 $0.5001 | ▼ −3.83% | ▼ −3.13% | $0.4480 (−13.85%) |
|
May 15, 2026
4w ago
|
8-K
| $0.5040 $0.5200 | ▲ +3.17% | ▲ +3.24% | $0.4480 (−11.11%) |
|
May 15, 2026
4w ago
|
Press Release
| $0.5040 $0.5200 | ▲ +3.17% | ▲ +3.24% | $0.4480 (−11.11%) |
|
May 11, 2026
5w ago
|
8-K
| $0.5300 $0.5300 | · 0.00% | ▼ −0.54% | $0.4480 (−15.47%) |
|
Mar 26, 2026
11w ago
|
DEFA14A
| $0.7520 $0.7310 | ▼ −2.79% | ▼ −2.43% | $0.4480 (−40.43%) |
|
Mar 5, 2026
14w ago
|
8-K
| $0.8240 $0.9000 | ▲ +9.22% | ▲ +8.38% | $0.4480 (−45.63%) |
|
Mar 5, 2026
14w ago
|
Press Release
| $0.8240 $0.9000 | ▲ +9.22% | ▲ +8.38% | $0.4480 (−45.63%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access